Pinned Tweet
#Afrezza
Afrezza effectively signaling the Hepatic Effect of Insulin. There is no alternative. It’s the reason there’s no pre bolus needed, the reason why Afrezza is 1-hour ahead of the race. The reason Afrezza gives a diabetic the choice to never go high!
#Afrezza #InhaledInsulin #OptimalUseOfAfrezza #T1D #Diabetes
Follow-up video and much more in the FB Afrezza users group, the greatest resource for everything Afrezza!
2
39
Timothy Brown retweeted
Presented by our partners at @MannKindCorp $MNKD: CEO Dr. Michael Castagna joins Boardroom Exclusives to discuss MannKind’s evolution into a diversified cardiometabolic and orphan lung company. From expanding inhaled insulin Afrezza into pediatrics and the recent launch of the Furoscix ReadyFlow autoinjector for fluid buildup associated with heart failure or chronic kidney disease, to advancing the company’s proprietary pipeline, including Nintedanib DPI (MNKD-201) for IPF, now in Phase 2.
The FDA has officially released MannKind from the long standing Afrezza pulmonary malignancy postmarketing requirement that dated back to the original 2014 approval.
Now the FDA says it’s no longer required.
Will this mean the removal of the black box warning? It should!
1
1
117
#Afrezza
Just another angle I hadn’t shared. Afrezza provides me with the highest quality of T1D life! Diabetes management is still on my mind 24/7, but it’s different with Afrezza. With Afrezza, I am in control. I have the power to Take Control of my diabetes.


























